More Hong Kong patients suffering from spinal muscular atrophy (SMA) will be able to enjoy a government subsidy to control ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

While leveraging the same mechanism of action as SPINRAZA® (nusinersen), but designed to achieve greater potency, salanersen can achieve high efficacy and enable once-yearly dosing.

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease SMA.

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

See the latest Ionis Pharmaceuticals Inc stock price (IONS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Spinal Muscular Atrophy Pipeline Therapies- OAV101, Risdiplam, Nusinersen, Amifampridine Phosphate, vesemnogene lantuparvovec, Olesoxime, NMD670 and others.

Background Spinal muscular atrophy (SMA) Type 1 is a neuromuscular disorder that has traditionally resulted in death from respiratory failure before 2 years of age. Treatment with Nusinersen, an ...

Methods Data was collected from the SMA REACH (Research and Clinical Hub) UK database, on the following three disease modifying treatments available in the UK. Nusinersen, an antisense oligonucleotide ...

Guest writer Joanna Buoniconti says that new treatments have granted her many things she's grateful for, including the ...